Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies

  title={Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies},
  author={Thilo Zander and Jia Xue and Gabriel Markson and Felix Dahm and Christoph Renner},
  journal={AntiCancer Research},
  pages={1821 - 1832}
Background/Aim: Satraplatin is an oral platinum analog with proven clinical efficacy and a more favorable toxicity profile, although with increased hematotoxicity, when compared to cisplatin. Hence, we carried out a systematic biomarker analysis to identify hematological malignancies with high susceptibility to satraplatin. Materials and Methods: Half-maximal inhibitory concentrations (IC50) for satraplatin and cisplatin were determined for 66 different cancer cell lines by CTG Luminescent Cell… 

Figures and Tables from this paper



Satraplatin: leading the new generation of oral platinum agents

Satraplatin has a favorable toxicity profile, and appears to have clinical activity against a variety of malignancies such as breast, prostate and lung cancer, and the oral route of administration and the intermittent schedule makes it very convenient for clinical use.

Preclinical antitumor activity of the oral platinum analog satraplatin

The results demonstrate that satraplatin and JM-118 have preclinical antitumor activity in human prostate cancer and other tumor types as well, including several cell lines displaying drug resistance to cisplatin, docetaxel and mitoxantrone.

Clinical and pharmacokinetic evaluation of satraplatin

Satraplatin is an investigational third-generation orally available lipophilic platinum, which has demonstrated safety and antitumor activity in multiple settings and may warrant development in settings that preclude cisplatin, for example, underlying renal dysfunction, elderly age and poor performance status.

Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance

The data suggest that the loss of p53 can increase oxaliplatin resistance but not satra platin resistance, and further molecular biology studies are needed to identify the activity of satraplatin in platinum-resistant cancer models and to determine whether this orally administered platinum analogue has synergistic effects in combination with other chemotherapy agents.

Primary CNS lymphoma commonly expresses immune response biomarkers

Based on TMB biomarker expression, over 90% of PCNSL patients may benefit from the use of immune checkpoint inhibitors.

Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines

The mutational profile of 11 diffuse large B-cell lymphoma (DLBCL) cell lines was analyzed using a customized high throughput sequencing panel to better characterize these cell lines and establish consensus on the mutational status of some functionally relevant genes.

Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity

The frequency of MTAP-deficiency is presented and past and recent strategies to target such deficient cells are discussed, including one in which MTA is administered, followed by very high doses of a toxic purine or pyrimidine analog.

CDKN2A–CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma

The genetic status of the CDKN2A–CDKN2B locus would be relevant in assessing patients with epidermotropic CTCLs in order to identify those cases where the disease was more aggressive.

Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts

The shapes of growth curves of ovarian carcinoma A2780 and its subline resistant to cisplatin after therapy with LA-12 were very similar, which shows that LA- 12 is able to overcome resistance to cis Platin.